Phase 2 multi-center, open-label study to evaluate the efficacy and safety of patient-specific immunotherapy, recombinant idiotype conjugated to KLH (Id-KLH) and administered with GM-CSF, in patients with follicular non-Hodgkin's lymphoma following primary treatment with rituximab and chemotherapy (R-Chemo)
Latest Information Update: 10 Nov 2021
At a glance
- Drugs GTOP 99 (Primary) ; Sargramostim (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Genitope Corporation
- 17 Mar 2008 Status changed from recruiting to discontinued as reported by ClinicalTrial.gov
- 30 May 2007 New trial record.